The results of this descriptive time and motion study suggest that switching to trastuzumab SC injection from trastuzumab IV infusion in a New Zealand oncology outpatient treatment setting decreases trastuzumab treatment-related tasks in the care unit, drug preparation time, chair time, and the volume and cost of consumables.
The optimized method was designed to be cost effective compared to existing extraction methods, which may require large quantities of consumables, produce substantial volumes of organic waste, or require costly instrumentation or equipment.
In addition, smaller sample volume and solvent requirements reduce the costs of consumables and the environmental footprint [28, 29].
Therefore, economics of consumables and most notably sample volume requirements are much lower for the biochip assay (100 μL total for evaluating nine analytes simultaneously, equal to 11.1 μL per analyte), which is an essential advantage concerning precious clinical samples.
The reduction in assay volumes substantially decreases reagent costs, although the instruments themselves require the purchase of consumables [ 24].
The first question depends on two things: dependability and the price of consumables.
Property prices rocketed and so did the cost of consumables and food.
Reduction of consumables cost by about 80% was achieved.
For an industrial use, the disadvantage of this new technology is the use of consumables but that could be reduced considerably in industrial production by using reusable consumables.
In addition, it decreases the cost of consumables and improves the quality of the overall analysis.
